Literature DB >> 26804248

Cisplatin resistance and opportunities for precision medicine.

Lauren Amable1.   

Abstract

Cisplatin is one of the most commonly used chemotherapy drugs, treating a wide range of cancer types. Unfortunately, many cancers initially respond to platinum treatment but when the tumor returns, drug resistance frequently occurs. Resistance to cisplatin is attributed to three molecular mechanisms: increased DNA repair, altered cellular accumulation, and increased drug inactivation. The use of precision medicine to make informed decisions on a patient's cisplatin resistance status and predicting the tumor response would allow the clinician to tailor the chemotherapy program based on the biology of the disease. In this review, key biomarkers of each molecular mechanism will be discussed along with the current clinical research. Additionally, known polymorphisms for each biomarker will be discussed in relation to their influence on cisplatin resistance. Published by Elsevier Ltd.

Entities:  

Keywords:  ABC transporters; Cisplatin resistance; Copper transporters; ERCC1; Glutathione; Nucleotide excision repair

Mesh:

Substances:

Year:  2016        PMID: 26804248     DOI: 10.1016/j.phrs.2016.01.001

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  137 in total

1.  ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.

Authors:  Tomasz B Owczarek; Takashi Kobayashi; Ricardo Ramirez; Lijie Rong; Anna M Puzio-Kuter; Gopa Iyer; Min Yuen Teo; Francisco Sánchez-Vega; Jingqiang Wang; Nikolaus Schultz; Tian Zheng; David B Solit; Hikmat A Al-Ahmadie; Cory Abate-Shen
Journal:  Cancer Res       Date:  2017-01-12       Impact factor: 12.701

2.  Atorvastatin and Caffeine in Combination Regulates Apoptosis, Migration, Invasion and Tumorspheres of Prostate Cancer Cells.

Authors:  Zhenshi Wang; Lanyue Zhang; Zheng Wan; Yan He; Huarong Huang; Hongping Xiang; Xiaofeng Wu; Kun Zhang; Yang Liu; Susan Goodin; Zhiyun Du; Xi Zheng
Journal:  Pathol Oncol Res       Date:  2018-05-24       Impact factor: 3.201

Review 3.  Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.

Authors:  Spyridon P Basourakos; Likun Li; Ana M Aparicio; Paul G Corn; Jeri Kim; Timothy C Thompson
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

Review 4.  Modulators of Redox Metabolism in Head and Neck Cancer.

Authors:  Xiaofei Chen; Jade Mims; Xiumei Huang; Naveen Singh; Edward Motea; Sarah M Planchon; Muhammad Beg; Allen W Tsang; Mercedes Porosnicu; Melissa L Kemp; David A Boothman; Cristina M Furdui
Journal:  Antioxid Redox Signal       Date:  2017-12-20       Impact factor: 8.401

5.  TBX2 expression is associated with platinum-sensitivity of ovarian serous carcinoma.

Authors:  Reiko Tasaka; Takeshi Fukuda; Masahiro Shimomura; Yuta Inoue; Takuma Wada; Masaru Kawanishi; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Oncol Lett       Date:  2017-12-29       Impact factor: 2.967

6.  PRMT1 expression predicts sensitivity to platinum-based chemotherapy in patients with ovarian serous carcinoma.

Authors:  Hiroaki Matsubara; Takeshi Fukuda; Yuichiro Awazu; Shigenori Nanno; Masahiro Shimomura; Yuta Inoue; Makoto Yamauchi; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Oncol Lett       Date:  2020-12-31       Impact factor: 2.967

Review 7.  Review of the Applications of Biomedical Compositions Containing Hydroxyapatite and Collagen Modified by Bioactive Components.

Authors:  Agnieszka Sobczak-Kupiec; Anna Drabczyk; Wioletta Florkiewicz; Magdalena Głąb; Sonia Kudłacik-Kramarczyk; Dagmara Słota; Agnieszka Tomala; Bożena Tyliszczak
Journal:  Materials (Basel)       Date:  2021-04-21       Impact factor: 3.623

Review 8.  Reviving the guardian of the genome: Small molecule activators of p53.

Authors:  Daniel Nguyen; Wenjuan Liao; Shelya X Zeng; Hua Lu
Journal:  Pharmacol Ther       Date:  2017-03-27       Impact factor: 12.310

9.  Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy.

Authors:  Ming-Yii Huang; Joh-Jong Huang; Chun-Ming Huang; Chih-Hung Lin; Hsiang-Lin Tsai; Ching-Wen Huang; Chee-Yin Chai; Chia-Yang Lin; Jaw-Yuan Wang
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

10.  Cisplatin resistance-associated circRNA_101237 serves as a prognostic biomarker in hepatocellular carcinoma.

Authors:  Shuping Zhou; Juan Wei; Yeliu Wang; Xinkuang Liu
Journal:  Exp Ther Med       Date:  2020-02-12       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.